Therapeutic Potential of Rexinoids in Cancer Prevention and Treatment

Retinoid X receptor (RXR) is a combinatorial partner for one third of the 48 human nuclear receptor superfamily members and acts as a master coordinator of nuclear receptor signaling pathways involved in the control of cell growth and differentiation. Thus, ligand-dependent simultaneous activation o...

Full description

Saved in:
Bibliographic Details
Published inCancer research (Chicago, Ill.) Vol. 69; no. 12; pp. 4945 - 4947
Main Authors TANAKA, Takemi, DE LUCA, Luigi M
Format Journal Article
LanguageEnglish
Published Philadelphia, PA American Association for Cancer Research 15.06.2009
Subjects
Antineoplastic agents
Antineoplastic Agents - pharmacology
Antineoplastic Agents - therapeutic use
Base Sequence
Biological and medical sciences
Humans
Ligands
Medical sciences
Neoplasms - drug therapy
Neoplasms - prevention & control
Pharmacology. Drug treatments
Retinoid X Receptors - drug effects
Retinoid X Receptors - metabolism
Tumors
Prevention
Treatment
Malignant tumor
Cancer
Online AccessGet full text

Cover

More Information
Summary:Retinoid X receptor (RXR) is a combinatorial partner for one third of the 48 human nuclear receptor superfamily members and acts as a master coordinator of nuclear receptor signaling pathways involved in the control of cell growth and differentiation. Thus, ligand-dependent simultaneous activation of multiple pathways is an attractive strategy for molecular-targeted therapy of neoplastic disease. However, clinical trials in RXR-targeted molecular therapy with the RXR ligand (rexinoid) have yielded disappointing outcomes. In this review, we discuss a possible mechanism underlying the loss of sensitivity to rexinoid therapy.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:0008-5472
1538-7445
DOI:10.1158/0008-5472.CAN-08-4407